Tumor suppressor gene RBM5 delivered by attenuated Salmonella inhibits lung adenocarcinoma through diverse apoptotic signaling pathways by Chen Shao et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Shao et al. World Journal of Surgical Oncology 2013, 11:123
http://www.wjso.com/content/11/1/123RESEARCH Open AccessTumor suppressor gene RBM5 delivered by
attenuated Salmonella inhibits lung
adenocarcinoma through diverse apoptotic
signaling pathways
Chen Shao1, Baoxue Yang4, Lijing Zhao2,3, Song Wang5, Jie Zhang1 and Ke Wang1*Abstract
Background: RBM5 (RNA-binding motif protein 5, also named H37/LUCA-15) gene from chromosome 3p21.3 has
been demonstrated to be a tumor suppressor. Current researches in vitro confirm that RBM5 can suppress the
growth of lung adenocarcinoma cells by inducing apoptosis. There is still no effective model in vivo, however, that
thoroughly investigates the effect and molecular mechanism of RBM5 on lung adenocarcinoma.
Method: We established the transplanted tumor model on BALB/c nude mice using the A549 cell line. The mice
were treated with the recombinant plasmids carried by attenuated Salmonella to induce the overexpression of
RBM5 in tumor tissues. RBM5 overexpression was confirmed by immunohistochemistry staining. H&E staining was
performed to observe the histological performance on plasmids-treated A549 xenografts. Apoptosis was assessed
by TUNEL staining with a TUNEL detection kit. Apoptosis-regulated genes were detected by Western blot.
Results: We successful established the lung adenocarcinoma animal model in vivo. The growth of tumor xenografts
was significantly retarded on the mice treated with pcDNA3.1-RBM5 carried by attenuated Salmonella compared to
that on mice treated with pcDNA3.1. Overexpression of RBM5 enhanced the apoptosis in tumor xenografts.
Furthermore, the expression of Bcl-2 protein was decreased significantly, while the expression of BAX, TNF-α,
cleaved caspase-3, cleaved caspase-8, cleaved caspase-9 and cleaved PARP proteins was significantly increased in
the pcDNA3.1-RBM5-treated mice as compared to that in the control mice.
Conclusions: In this study, we established a novel animal model to determine RBM5 function in vivo, and
concluded that RBM5 inhibited tumor growth in mice by inducing apoptosis. The study suggests that although
RBM5’s involvement in the death receptor-mediated apoptotic pathway is still to be investigated, RBM5-mediated
growth suppression, at least in part, employs regulation of the mitochondrial apoptotic pathways.
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Lung cancer is the leading cause of cancer death
worldwide, with over a million deaths annually [1,2].
The five-year survival rate has not improved dramat-
ically throughout the past three decades despite inno-
vations in diagnostic testing, surgical technique, and
development of new chemotherapeutic agents [3,4].* Correspondence: wke@jlu.edu.cn
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reproduction in any medium, provided the orLung cancer histology is heterogeneous. Small cell
lung carcinomas (SCLCs) account for 20% of all lung
cancers, and the remaining 80% consists of non-small
cell lung carcinomas (NSCLCs) which, in turn, is fur-
ther subclassified into 40% adenocarcinoma (AC), 40%
squamous cell carcinoma (SCC) and 20% large cell
carcinoma. Delineating genetic alterations specific to
each subtype of lung cancer may be the most effective
way of discovering molecular markers for early detec-
tion and developing better individualized treatment.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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critical step in the pathogenesis of human lung cancer.
The earliest premalignant chromosomal aberration in
human lung cancers is allele loss within the short arm of
chromosome 3 at 3p21.3 [5]. This loss of heterozygosity
occurs in practically all (>95%) SCLC tumors, the major-
ity (>70%) of NSCLC tumors [6-8]. Deletion at chromo-
some 3p21.3 is also the most frequent genetic alteration
identified in lung cancer. The region contains 19 TSGs
[9], most of which demonstrate varying degrees of tumor
suppressor activity (related to the control of processes
such as cell differentiation, proliferation, signal trans-
duction, and apoptosis). It has been suggested that all
function together as a large, integrated, biologically func-
tionally diverse tumor suppressor unit [7].
RNA-binding motif protein 5 (RBM5, previously re-
ferred to as g15, LUCA-15, and H37) that maps to one
end of this 19-gene deletion breakpoint, is an RNA-
binding protein that has the ability to modulate apoptosis
and cell cycle arrest through pre-mRNA splicing of mul-
tiple target genes, such as p53 [10-17]. Overexpression of
RBM5, which is also involved in the regulation of alterna-
tive splicing, showed the function of inhibiting tumor
growth and reducing the metastatic potential [18-20]. In
addition, multiple protein isoforms of RBM5 exist, each
possessing apoptosis modulatory activity, a function con-
sistent with tumor suppressor activity. For the inhibitory
effect of RBM5 on lung cancer, in current studies, it is
reported that RBM5 modulates apoptosis by regulating
the alternative splicing of apoptosis-associated pre-
mRNAs, such as CASP2 and FAS/CD95 [2,21]. In Oh’s
study, they found RBM5 could significantly inhibit the
growth of A549 non-small cell lung cancer cells by in-
ducing apoptosis, which is associated with upregulation
of the proapoptotic protein BAX, increased release of
mitochondrial cytochrome C into the cytosol and in-
creased activation of caspases 9 and 3 [12,14,16]. Most
of the researches, however, were restricted to the cell
line in vitro. In addition, in most of these approaches,
the therapeutic agents could not reach the tumors in
effective doses, or were distributed to unwanted sites
and degraded by nucleases resulting in limited antitumor
effects. Currently, there is not an effective animal model
for further in vivo exploration of the function and mech-
anism of RBM5 on primary lung cancer. Furthermore,
how to deliver a vector overexpressing RBM5 to the
tumor-specific part is the key point for the study in vivo.
Fortunately, the discovery that genes in bacterial vectors
can be functionally transferred to mammalian cells sug-
gests that it might be possible to use bacterial vectors as
vehicles for gene therapy. Genetically modified nonpatho-
genic bacteria have been used as potential antitumor
agents, to either elicit direct tumoricidal effects or deliver
tumoricidal molecules [22]. Bioengineered attenuatedstrains of Salmonella enterica serovar Typhimurium have
been shown to preferentially accumulate by >1000-fold in
tumors compared with normal tissues and to become
homogeneously dispersed in the tumor tissues [23]. These
attenuated bacteria have been proven safe in mice, pigs
and monkeys when administered intravenously [22].
In this study, we first establish an effective animal
model using BALB/c nude mice treated with attenuated
Salmonella as a vector carrying plasmids to explore the
molecular mechanisms involved in the antitumor effect
induced by RBM5 on lung adenocarcinoma.
Methods
Cell line and plasmids
The A549 cell line was purchased from the American
Tissue Type Collection (Manassas, VA, USA). Cells were
grown in RPMI 1640 supplemented with 10% fetal
bovine serum as previously described [24]. Plasmids
of pcDNA3.1 and pcDNA3.1-RBM5 were generously
provided by Dr. Leslie Sutherland of the Research Pro-
gram, Northeast Cancer Centre, Health Sciences North,
Ontario, Canada.
Electrotransfection of RBM5 into competent attenuated
Salmonella cells
Competent S. enterica ser. Typhimurium cells (compe-
tence) were obtained from the China-Japan Union Hospital
of Jilin University in China. The competence were mixed
with 1 μg pcDNA3-RBM5 or 1 μg pcDNA3 plasmids and
cooled for 15 minutes on ice, Then the DNA could be
transfected into the competence under the conditions
as follows: C = 25 μF, PC = 200 ohm, V = 1.25 kV
(12.5 kV/cm). Then the competence with DNA should
be quickly transferred into LB Ager medium for prolif-
eration at 37°C. The recombinant attenuated Salmon-
ella strains carrying plasmids were stored at −80°C for
later use.
Establishment of A549 xenografts
BALB/c athymic nude male mice (nu/nu; 6 weeks) were
purchased from the Institute of Zoology, Chinese Acad-
emy of Sciences, Beijing. Use of animals was in accord-
ance with Animal Care guidelines and the protocol was
approved by Jilin University Animal Care Committee.
A549 cells were washed and resuspended in phosphate-
buffered saline (PBS). The suspension (5 × 106 cells in
150 μL per mouse) was inoculated subcutaneously into
the right flanks of nude mice. The sizes of the tumors
were measured using calipers starting from day 7 after
cell injection until day 42.
Gene treatment
The tumor-bearing mice were divided randomly into two
groups (six mice per group) at day 21 after cell injection.
Figure 1 RBM5 inhibits tumor growth in vivo. Tumor-bearing
mice were treated with attenuated Salmonella carrying pcDNA3.1 or
pcDNA3.1-RBM5 by injection two times (on day 28 and 35).
(A) Comparison of tumor sizes in two groups on day 42 after
implantation. (B) Tumor growth curve. Tumor sizes were measured
two times every week from day 7 to 42 after implantation. (C) Tumor
wet weights were measured when the mice were sacrificed on day 4
after implantation. *indicates significant difference as compared to
the control (P <0.05); **indicates significant difference as compared
to the control (P <0.01). RBM5, RNA-binding motif protein 5.
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through a tail mainline as follows: (a) control group
(attenuated Salmonella carrying pcDNA3.1); (b) RBM5
group (attenuated Salmonella carrying pcDNA3.1-
RBM5) (108 colony-forming units (CFU) per 50 μL
PBS). Then the tumors were measured using calipers
every 3.5 days until day 42. The data were plotted using
the Kaplan-Meier method to analyze the tumor growth
curves. The wet weight and size of the tumors were
measured when the mice were sacrificed on day 42.
The tumor blocks were taken out, a part of which
was fixed in formalin for hematoxylin and eosin
(H&E) staining and immunohistochemistry analysis,
and another part of which was snap frozen in liquid
nitrogen immediately for Western blot and terminal
deoxyuridyl transferase (TdT)-mediated deoxyuridine
5'-triphosphate (dUTP) nick-end labeling (TUNEL)
assay (Roche, Penzberg, Germany).
TUNEL staining of apoptotic cells
The tissue sections of xenografts from the nude mice
were dewaxed and hydrated and then were subjected to
TUNEL staining following the instructions provided by
the manufacturer (Promega, Madison, WI, USA). Four
fields were chosen randomly and analyzed. The apoptotic
index was defined as follows: apoptotic index (%) = 100×
apoptotic cells/total tumor cells.
H&E and immunohistochemistry staining
Tumors treated with recombinant Salmonella strains
carrying different plasmids were H&E stained. Immuno-
histochemistry analyses were carried out as described pre-
viously [25,26]. Anti-human rabbit RBM5 antibody was
purchased from Abcam (Cambridge, MA, USA).
Protein extraction and Western blot
Total proteins from both tumor tissues were extracted
according to the previous study [27]. Protein samples
(30 ug) were then separated by SDS-PAGE and trans-
ferred onto a PVDF membrane (Millipore, Bedford, MA,
USA). The primary antibodies were rabbit anti-human
RBM5, Bcl-2, Bax, TNF-α, cleaved PARP, cleaved caspase-3,
cleaved caspase-8, cleaved caspase-9 and β-actin antibodies
from Abcam (Cambridge, MA, USA). The second antibody
was a goat anti-rabbit IgG-HRP from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Western blot was carried
out as previously described [27]. The protein bands were
visualized by SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific Pierce, Rockford, IL, USA),
and the membranes were subjected to X-ray autoradiog-
raphy. Band intensities were determined with Quantity
One software (Bio-Rad, Hercules, CA, USA). Furthermore,
we confirmed the reproducibility of the experiments at least
three times.Statistical analysis
Statistical comparisons were performed using analysis of
variance to determine the significance of differences ob-
served between different treatment groups. Values are
expressed as mean ± standard deviation (SD) from at
least three separate experiments in which each experi-
ment had six samples per treatment group and differ-
ences were considered significant at a P value of <0.05.
Results
Overexpression of RBM5 inhibited tumor growth in A549
xenograft BALB/c nude mice
The potential therapeutic effect on lung adenocarcinoma
xenograft growth by RBM5 was examined in tumor-
bearing mice treated with bacteria carrying RBM5 plas-
mid (Figure 1A). Dynamic tumor growth was monitored
from day 7 to day 42 after injection. We showed that,
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control groups were similar before day 28, the growth of
tumor xenografts in the mice treated with RBM5 retarded
after day 28 (Figure 1B). In addition, the weight of the
tumor xenografts from mice treated with RBM5 became
significantly lighter than that in the control group at day
42 when the mice were sacrificed (Figure 1C). This result
suggested that accumulative and stable expression of
RBM5 in A549 xenograft BALB/c nude mice significantly
retarded the tumor growth rate in vivo. Moreover, we
established a novel animal model using BALB/c nude mice
treated with attenuated Salmonella as a vector carrying
plasmids to determine RBM5 function in vivo.
Analysis of apoptosis induced by RBM5 in A549 xenograft
BALB/c nude mice
To determine the potential mechanism of tumor growth
inhibition in vivo, A549 xenograft treated with pcDNA3.1
control or pcDNA3.1-RBM5 were excised and analyzed
by immunohistochemistry, H&E, and TUNEL staining.Figure 2 H&E, immunohistochemistry and TUNEL assay. (A) Immunoh
indicates cancer nest. (C) RBM5-induced apoptosis shown by TUNEL stainin
transferase to incorporate fluorescein-deoxyuridine 5'-triphosphate (dUTP) t
nuclear green fluorescence were detected by fluorescence microscopy. Ad
each group showing equal cell density and fixation. RBM5, RNA-binding mFirst, the overexpression of RBM5 was confirmed by im-
munohistochemistry staining. As shown in Figure 2A,
RBM5 expression was significantly higher in the tumors
of mice treated with pcDNA3.1-RBM5, compared to that
in the tumors of mice treated with pcDNA3.1. This result
suggested that the RBM5 protein was efficiently delivered
and overexpressed by attenuated Salmonella in vivo.
We next employed H&E staining to observe the
histopathological performance on A549 xenografts. The
result showed that there were a large number of cancer
nests in the control group (Figure 2B), and the tumor
tissue could survive in a good state. It could be seen,
however, in the RBM5 group, that the number of can-
cer nests significantly decreased, and the regions of ne-
crosis were much larger than those in the control group
(Figure 2B).
To explore the contribution of cell death and tumor
retardation induced by RBM5, we performed TUNEL
staining analysis to detect apoptotic cells in A549 xeno-
grafts. As shown in Figure 2C, approximately more thanistochemistry staining for RBM5 (400×). (B) H&E staining (200×). ‘↑’
g (400×). Tissue sections were treated with terminal deoxynucleotidyl
o nicked DNA of apoptotic cells. Apoptotic cells exhibiting a strong
jacent light microscopic photos showed a representative area from
otif protein 5.
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group compared with those in the control group, which
indicated that RBM5 inhibited A549 xenograft tumor
growth by inducing apoptosis.
Analysis of mitochondrial and TNF-α related apoptotic
pathways in RBM5 mediated-apoptosis
To further characterize the molecular mechanisms of
the RBM5-mediated apoptotic pathways, we investigated
the influence of mitochondrial apoptosis signaling and
death receptors that characteristically initiate signaling.
We examined the expression of some apoptosis-related
genes including RBM5, Bcl-2, Bax, and TNF-α, cleaved
caspase-3, cleaved caspase-8, cleaved caspase-9 and
cleaved PARP. We observed that the expression of Bcl-2
protein was decreased significantly when RBM5 was
overexpressed, while the expression of Bax, TNF-α,
cleaved caspase-3, cleaved caspase-3, cleaved caspase-
8, cleaved caspase-9 and cleaved PARP proteins were
significantly increased in the RBM5 group as com-
pared to that in the control cells (Figure 3), which
suggested that, although involvement of RBM5 in the
death receptor-mediated apoptotic pathway remains
to be investigated in depth, RBM5- mediated growth
suppression, at least in part, employs regulation of the
mitochondrial apoptotic pathways.Figure 3 Differential expression of apoptosis regulatory proteins asso
performed to compare expression levels of various apoptosis-related prote
expression was found to be decreased and RBM5, TNF-α, Bax, cleaved casp
increased in the RBM5 group compared with the control. β-actin was usedDiscussion
In recent years, lung cancer has become one of the lead-
ing causes of cancer-related death worldwide [1,2]. Des-
pite innovations in diagnostic testing, surgical technique,
and development of new chemotherapeutic agents, five-
year survival rate has not improved dramatically for pa-
tients with lung cancer [3,4]. Therefore, it is important
to understand the molecular mechanisms involved in
the pathogenesis and progression of metastasis to iden-
tify novel therapeutic targets and develop effective treat-
ment strategies.
Deletion within the lung cancer tumor suppressor re-
gion at 3p21.3 constitutes the earliest premalignant
chromosomal aberration in human lung cancers. Nine-
teen tumor suppressor genes (TSGs) reside to this region
at 3p21.3. RBM5 maps to one end of this 19-gene dele-
tion breakpoint, which is more frequently observed in tu-
mors of lung, breast and kidney [28], and is not included
in a slightly smaller 17-gene deletion that is common to
breast and renal tumors [28]. There is increasing evi-
dence suggesting that RBM5 plays an important role in
lung cancer occurrence and development, nevertheless,
there are few studies reporting on RBM5 expression in
lung cancer tissues and tumor cell lines. In a very small
cohort of eleven specimens, it was observed that the six
tumor samples with the most significantly reduced RBM5ciated with RBM5 overexpression. Western blot analysis was
ins between the RBM5 and control groups. Among them, Bcl-2
ase-3, cleaved caspase-8, cleaved caspase-9 and cleaved PARP
as a protein-loading control. RBM5, RNA-binding motif protein 5.
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three of the nine with the less significantly reduced
RBM5 mRNA levels were adenocarcinomas. The one
tumor sample with no change in RBM5 mRNA expres-
sion compared to its non-tumor tissue was an adeno-
carcinoma, while the one tumor sample that had more
RBM5 mRNA than its non-tumor tissue was a large cell
carcinoma [29,31]. In our current study, we found that
the expression of RBM5 mRNA and protein were both
significantly reduced in 120 cases of surgically resected
NSCLC compared to the adjacent normal tissues, 30 of
which were lung adenocarcinoma [32]. All the above
suggest the critical and specific role of RBM5 in the de-
velopment of lung cancer.
This report represents the first characterization of
RBM5 tumor suppressive activity and its molecular
mechanism in a lung adenocarcinoma animal model.
We successfully established lung adenocarcinoma ani-
mal models in vivo on the back of nude mice. We found
that RBM5 significantly inhibited the growth of lung
adenocarcinoma in vivo by the induction of apoptosis.
In Oh’s study, they also reported that RBM5 could in-
hibit the growth of human lung cancer A549 cells
in vitro and in vivo [16]. The model they mentioned,
however, was simply established using RBM5 stable
transfected A549 cells to observe the growth retard-
ation of tumor, without any metabolism for RBM5 in
animals. Salmonella enterica ser. Typhi Ty21a has
many of the desirable properties of a delivery vector,
including targeting of multiple tumors from a distant
inoculation site, selective replication within tumors,
and the ability to express effector genes. Salmonella
enterica ser. Typhi Ty21a has an excellent safety profile
and a propensity for homing to tumors. In this study,
we chose an efficient gene delivery system, attenuated
S. enterica ser. Typhimurium, which could selectively
target tumors and deliver the therapeutic agents into
tumors while reducing the damage to normal tissue
[23,33,34]. More recently, these bacteria have been
engineered to express numerous genes, including survivin
[35], MDM2 [36], Neu3 [37] and STAT3 siRNA [25]
against prostate cancer in our laboratory. So this time, we
first employed the attenuated S. enterica ser. Typhimurium
to target lung tumors and directly deliver the therapeutic
pcDNA3.1-RBM5 plasmids through the tail by intraven-
ous injection.
Apoptosis is a complex, multistage process involving
many genes. Among the wide spectrum of apoptosis
regulatory proteins tested in our studies, the expression
of proapoptotic proteins Bax, cleaved caspase-9, cleaved
caspase-3, and cleaved PARP were found to be increased
in RBM5-overexpressing tumor tissues, while the expres-
sion of apoptosis inhibitory protein Bcl-2 was observed
at a lower level in RBM5-overexpressing tumor tissues.Thus, we conclude that RBM5 might induce apoptosis
by triggering the mitochondrial apoptotic pathways, in-
cluding caspase-9 and caspase-3 activations by means
of increasing the expression of Bax and decreasing the
expression of Bcl-2 [38]. In Oh’s study, mitochondrial
apoptotic pathways initiated by Bax were also observed
in the A549 cells transfected with RBM5 in vitro [16].
In addition, we also noted that increased expression of
TNF-α and cleaved caspase-8 was associated with the
RBM5 overexpression in tumor tissues. This finding,
although it needs to be validated by further experi-
ments, strongly suggested that RBM5 could initiate
TNF-α-mediated apoptosis [39], in which capase-8,
caspase-3 and PARP were activated. This potential
apoptosis pathway induced by RBM5 could also be
observed in human breast carcinoma MCF-7 cells [40,41]
and leukemia Jurkat cells [42]. The current data suggest
that although RBM5’s involvement in the death receptor-
mediated apoptotic pathway is still to be investigated in
depth, RBM5-mediated growth suppression, at least
in part, employs regulation of the mitochondrial apop-
totic pathways.
Conclusions
In summary, we recently demonstrated that RBM5
overexpression can employ both TNF-α-mediated apop-
totic pathways and mitochondrial apoptotic pathways
to suppress the growth of lung adenocarcinoma, by
establishing an implant tumor model in vivo, treated
with attenuated Salmonella-RBM5, a plasmids delivery
system. Our studies provide further data in vivo to ex-
plore the role and molecular mechanism of RBM5 in
lung cancer pathogenesis and suggest a strategy for the
development of rationally designed therapeutics using
RBM5 as a target.
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